Lobe Sciences Ltd
Lobe Sciences Ltd., a biopharmaceutical company, engages in the research and development of lipid technology to develop innovative treatments for orphan and rare diseases. It offers Altemia® MF, a medical food designed to manage deficiencies in sickle cel disease. Lobe Sciences Ltd. was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. The … Read more
Lobe Sciences Ltd - Asset Resilience Ratio
Lobe Sciences Ltd (LOBEF) has an Asset Resilience Ratio of 14.47% as of November 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Lobe Sciences Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Lobe Sciences Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.03 Million | 14.47% |
| Total Liquid Assets | $1.03 Million | 14.47% |
Asset Resilience Insights
- Moderate Liquidity: Lobe Sciences Ltd has 14.47% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Lobe Sciences Ltd Industry Peers by Asset Resilience Ratio
Compare Lobe Sciences Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Lobe Sciences Ltd (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Lobe Sciences Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-08-31 | 22.23% | $1.69 Million | $7.59 Million | -- |
| 2022-08-31 | 0.00% | $0.00 | $1.75 Million | -- |
| 2021-08-31 | 51.94% | $6.28 Million | $12.10 Million | -- |
| 2020-08-31 | 0.00% | $0.00 | $12.97 Million | -- |